Tempest Therapeutics

TPST

Market cap $15.2M

TPST Hedge Fund Activity: Q1 2026 in Review

22 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Tempest Therapeutics (TPST) for Q1 2026, worth a combined $1.29M — down 43% from $2.26M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new TPST positions and 2 closed out — a net gain of 3 holders — while 3 added to existing stakes and 3 trimmed.

The largest buyer was Geode Capital Management, adding an estimated $103K. The largest seller was Sabby Management, cutting an estimated $388K.

• 22 institutional investors held Tempest Therapeutics (TPST) as of Q1 2026, up from 21 in Q4 2025.
• Funds reported $1.29M of Tempest Therapeutics stock for Q1 2026, down 43% quarter-over-quarter.
• 5 funds opened new Tempest Therapeutics positions in Q1 2026 and 2 closed out, a net change of +3 holders.
• The largest Tempest Therapeutics buyer in Q1 2026 was Geode Capital Management, an estimated $103K added.
• The largest Tempest Therapeutics seller in Q1 2026 was Sabby Management, an estimated $388K sold.

Based on aggregated 13F filings for Q1 2026.